Comparison of Outcomes Between Protocolized Tacrolimus‐Based and Non‐Protocolized Ciclosporin‐Based Triple‐Combination Therapy in Interstitial Lung Disease With Anti‐MDA5‐Positive Dermatomyositis: A Single‐Center Retrospective Cohort Study

Protocolized tacrolimus-based triple-combination therapy demonstrated better outcomes than non-protocolized ciclosporin-based triple-combination therapy in patients with anti-MDA5-positive DM-associated ILD. Reduced GC doses and more intensive IVCY use also presumably contributed to better outcomes in the protocolized therapy with the tacrolimus group.